reflected in the report “Social and Economic Burden of Insomnia in Adults”. Produced by RAND Europe, an international non-profit research organization affiliated with India. 15% of her adults suffer from chronic insomnia.
The purpose of this study is to understand the impact of sleep deprivation beyond its impact on health and healthcare.
Study abroad in 16 countries
We therefore analyze the impact of this disorder in relation to indirect economic costs (medical and intangible costs) that are not directly detected in economic transactions but affect human health and well-being. -.
It operates in 16 countries including Germany, Australia, Austria, Belgium, Canada, Spain, USA, Finland, France, Greece, Italy, Norway, Portugal, UK, Sweden and Switzerland.
According to the report, 50% of working adults, a total of 172 million people, suffer from insomnia. Up to 25%, clinical insomnia (72 million). and 15% have chronic insomnia (42 million), its severe form.
Economic Impact of Sleeplessness
Sleep deprivation has an economic impact of reduced work productivity each year, as adults who suffer from sleep deprivation are more likely to miss work, resulting in lower performance.
Specifically, in terms of overhead costs, the report explains: Chronic insomnia is associated with 11-18 days of absenteeism39-45 days of downtime and 44-54 days of typical production loss per year.
Thus, the indirect costs of this disability in terms of reduced labor productivity amount to €160-185 billion, equivalent to a total gross domestic product (GDP) of €372 billion.
A further 16 countries analyzed intangible welfare losses of EUR 130-113.3 billion annually (213.6 billion EUR in total).
For Spain, annual labor productivity losses amount to €10,703 million.
Given all of this, the study’s economic projections suggest that eliminating the effects of insomnia through policies of “prevention, education, regular diagnosis and early treatment” will increase workplace productivity and have a positive impact on GDP. gives
need a restful sleep
Research also revealed Intangible cost Insomnia is caused because it leads to a decrease in quality of life.
Therefore, according to the same paper, adults who suffer from insomnia are willing to give up 14% of their household’s annual per capita income in exchange for achieving the same level of life satisfaction as those who do not suffer from insomnia. .
In this sense Labor Economy and Industry Committee Coordinator alliance for dreams, AS Dr. Carmen Beautiful CambronHe points out that “employees need quality, restful sleep” for proper occupational health.
“There is a two-way relationship between sleep and work,” said Berito, a researcher and coordinator of the Occupational Risk Prevention Service at De Castellon Hospital.
“If you don’t sleep well at night, you will be less productive during the day, less motivated, less satisfied with your job, and more likely to conflict with your colleagues at work.” , can impair mental health,” the researchers said. .
But sleep deprivation also impacts employee frustration, resilience, emotion management, and conflicts at work, and has a significant impact on the organization as a whole, Berito continues.
strategy against him
“Interventions to reduce insomnia, whether at the primary, secondary or tertiary level of prevention, are of critical importance to public health and organizations, promoting improved employee health and well-being. It’s important to establish preventive programs against this occupational hazard,” experts say.
This study highlights the need to: many strategies Address and mitigate the impact of this disorder at the level of politics, research and clinical practice.
These include integrating sleep into national health strategies, promoting public health campaigns highlighting the importance of proper sleep hygiene, and systematic early detection of insomnia through regular medical visits through screening. Masu.
Similarly, we recommend establishing coordinated protocols at various levels to ensure timely diagnosis and access to treatment for patients.
All of this will enable medical schools to provide “new” training on this disease and gain access and reimbursement for safe, science-backed pharmacological discoveries.